{"date":"2025-08-23","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6589-2025-08-23-1351-1aozi9x","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-08-23","time":"13:51:59","subject":"本公司研發中產品EG1206A(pertuzumab生物相似藥)，獲得泰國食品藥物管理局同意進行第三期臨床試驗","clause":"第10款","fact_date":"2025-08-22","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-08-23 13:51，「本公司研發中產品EG1206A(pertuzumab生物相似藥)，獲得泰國食品藥物管理局同意進行第三期臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}